Cargando…

Immunotherapy for Uterine Cervical Cancer

Cervical cancer is a malignant neoplastic disease that is the fourth most commonly occurring cancer in women worldwide. Since the introduction of angiogenesis inhibitors, treatments for recurrent and advanced cervical cancers have improved significantly in the past five years. However, the median ov...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kagabu, Masahiro, Nagasawa, Takayuki, Fukagawa, Daisuke, Tomabechi, Hidetoshi, Sato, Saiya, Shoji, Tadahiro, Baba, Tsukasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787701/ https://www.ncbi.nlm.nih.gov/pubmed/31533297 http://dx.doi.org/10.3390/healthcare7030108

Ejemplares similares

Immunotherapy for Uterine Cervical Cancer Using Checkpoint Inhibitors: Future Directions
por: Kagabu, Masahiro, et al.
Publicado: (2020)

Comparison of Postoperative Adjuvant Chemotherapy and Concurrent Chemoradiotherapy for FIGO2018 Stage IIIC1 Cervical Cancer: A Retrospective Study
por: Kagabu, Masahiro, et al.
Publicado: (2021)

A New Therapeutic Strategy for Recurrent Ovarian Cancer―Bevacizumab beyond Progressive Disease
por: Shoji, Tadahiro, et al.
Publicado: (2019)

Expectations and Challenges of First-Line Maintenance Therapy for Advanced Ovarian Cancer
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Novel Therapeutic Strategies for Refractory Ovarian Cancers: Clear Cell and Mucinous Carcinomas
por: Shoji, Tadahiro, et al.
Publicado: (2021)

A Phase II Study of S-1 plus Oxaliplatin for Patients with Recurrent Non-Squamous Cell Carcinoma of the Uterine Cervix (Tohoku Gynecologic Cancer Unit: TGCU206 Study)
por: Nagasawa, Takayuki, et al.
Publicado: (2023)

Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2]
por: Takeuchi, Satoshi, et al.
Publicado: (2020)

Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor
por: Kagabu, Masahiro, et al.
Publicado: (2023)

A retrospective study of neoadjuvant chemotherapy plus radical hysterectomy versus radical hysterectomy alone in patients with stage II cervical squamous cell carcinoma presenting as a bulky mass
por: Takatori, Eriko, et al.
Publicado: (2016)

Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass
por: Shoji, Tadahiro, et al.
Publicado: (2016)

Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix
por: Shoji, Tadahiro, et al.
Publicado: (2012)

Safe administration of bevacizumab combination chemotherapy for the patients with recurrent cervical cancer after pelvic radiotherapy: Two case reports
por: Shoji, Tadahiro, et al.
Publicado: (2018)

Clinical and reproductive outcomes of fertility-sparing surgery in stage I epithelial ovarian cancer
por: Watanabe, Takafumi, et al.
Publicado: (2020)

Changes of uterine blood flow after vaginal radical trachelectomy (VRT) in patients with early-stage uterine invasive cervical cancer
por: Umemura, Kota, et al.
Publicado: (2010)

Genome-wide analysis of microRNA to evaluate prognostic markers in isolated cancer glands and surrounding stroma in high-grade serous ovarian carcinoma
por: Sato, Chie, et al.
Publicado: (2020)

Protein expression patterns in cancer-associated fibroblasts and cells undergoing the epithelial-mesenchymal transition in ovarian cancers
por: Fukagawa, Daisuke, et al.
Publicado: (2018)

A recurrent ovarian cancer patient with a history of nine prior chemotherapy regimens who was safely treated with weekly paclitaxel plus bevacizumab and achieved a complete response: a case report
por: Takatori, Eriko, et al.
Publicado: (2015)

Adjuvant immunotherapy for cancer: both dendritic cell-priming and check-point inhibitor blockade are required for immunotherapy
por: SEYA, Tsukasa, et al.
Publicado: (2018)

Updated applications of Ultrasound in Uterine Cervical Cancer
por: Hsiao, Yi-Hsuan, et al.
Publicado: (2021)

The Evolving Landscape of Immunotherapy in Uterine Cancer: A Comprehensive Review
por: Hamoud, Bashar Haj, et al.
Publicado: (2023)

Immunologic treatments for precancerous lesions and uterine cervical cancer
por: Vici, Patrizia, et al.
Publicado: (2014)

Brain Metastases from Uterine Cervical and Endometrial Cancer
por: Kato, Mayumi Kobayashi, et al.
Publicado: (2021)

Successful pregnancy with stage IB2 uterine cervical cancer: A case report
por: Nagasawa, Saya, et al.
Publicado: (2021)

Combinations of radiotherapy with immunotherapy in cervical cancer
por: Yang, Xiaojing, et al.
Publicado: (2022)

A case of primary ovarian signet-ring cell carcinoma treated with S-1/CDDP therapy
por: Shoji, Tadahiro, et al.
Publicado: (2020)

Preliminary Analysis of Cervical Cancer Immunotherapy
por: Ma, Zhen, et al.
Publicado: (2022)

Intensity-modulated radiation therapy with the central shielding technique for patients with uterine cervical cancer
por: Torii, Akira, et al.
Publicado: (2023)

Expression of IP-10 related to angiogenesis in uterine cervical cancers
por: Sato, E, et al.
Publicado: (2007)

Emerging Biological Treatments for Uterine Cervical Carcinoma
por: Vici, Patrizia, et al.
Publicado: (2014)

Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
por: Fleischmann, Maximilian, et al.
Publicado: (2021)

Application of PDT for Uterine Cervical Cancer
por: Muroya, T., et al.
Publicado: (1999)

NK Cell Regulation in Cervical Cancer and Strategies for Immunotherapy
por: Gutiérrez-Hoya, Adriana, et al.
Publicado: (2021)

Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
por: Turinetto, Margherita, et al.
Publicado: (2022)

Clinical and MRI Characteristics of Uterine Cervical Adenocarcinoma: Its Variants and Mimics
por: Saida, Tsukasa, et al.
Publicado: (2019)

Myeloid-Derived Suppressor Cells as Therapeutic Targets in Uterine Cervical and Endometrial Cancers
por: Mabuchi, Seiji, et al.
Publicado: (2021)

Use of Smartphones for the Detection of Uterine Cervical Cancer: A Systematic Review
por: Champin, Denisse, et al.
Publicado: (2021)

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2021)

UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study
por: Matsuoka, Hideki, et al.
Publicado: (2020)

Evaluation of elderly women with uterin cervical cancer
por: Birge, Özer, et al.
Publicado: (2021)

Advances in immunotherapy for cervical cancer
por: Grau-Bejar, Juan Francisco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2j2c28r3e2pcjrgq03ru0tve6j